<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02332031</url>
  </required_header>
  <id_info>
    <org_study_id>17436</org_study_id>
    <secondary_id>2014-001907-36</secondary_id>
    <nct_id>NCT02332031</nct_id>
  </id_info>
  <brief_title>Sorafenib Drug Drug Interaction Study in Healthy Male Subjects</brief_title>
  <official_title>An Open-label Study in Healthy Male Subjects to Assess the Effect of Hyperthyroidism Mimicked by Oral Dosing of Levothyroxine on the Pharmacokinetics of Sorafenib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of levothyroxine on the absorption, distribution, metabolization and
      elimination of sorafenib and safety in healthy male subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration vs. time curve from zero to infinity after single (first) dose (AUC) of sorafenib</measure>
    <time_frame>Period 1 Day 1 and Period 2 Day 11: Predose and at 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 h post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC from time 0 to the last data point &gt; LLOQ (AUC(0-tlast))of Sorafenib and metabolite M-2</measure>
    <time_frame>Period 1 Day 1 and Period 2 Day 11: Predose and at 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of Sorafenib and metabolite M-2</measure>
    <time_frame>Period 1 Day 1 and Period 2 Day 11: Predose and at 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (in case of two identical Cmax values, the first tmax will be used) (Tmax Sorafenib) and metabolite M-2</measure>
    <time_frame>Period 1 Day 1 and Period 2 Day 11: Predose and at 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life associated with the terminal slope (t1/2) of Sorafenib and metabolite M-2</measure>
    <time_frame>Period 1 Day 1 and Period 2 Day 11: Predose and at 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at steady state after extravascular administration (Vss/F) of Sorafenib</measure>
    <time_frame>Period 1 Day 1 and Period 2 Day 11: Predose and at 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance of Sorafenib calculated after extravascular administration (CL/F)</measure>
    <time_frame>Period 1 Day 1 and Period 2 Day 11: Predose and at 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of metabolite M-2</measure>
    <time_frame>Period 1 Day 1 and Period 2 Day 11: Predose and at 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite to parent AUC(0-tlast) ratios</measure>
    <time_frame>Period 1 Day 1 and Period 2 Day 11: Predose and at 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 15 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Drug Interactions</condition>
  <arm_group>
    <arm_group_label>Sorafenib (Nexavar, BAY43-9006) &amp; Levothyroxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib be administrated without and with levothyroxine orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib (Nexavar, BAY43-9006)</intervention_name>
    <description>Single dose of 400 mg orally on Period 1 Day 1 and Period 2 Day 11</description>
    <arm_group_label>Sorafenib (Nexavar, BAY43-9006) &amp; Levothyroxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine</intervention_name>
    <description>Single dose of 300 mcq orally from Period 2 Day 1 to Period 2 Day 14</description>
    <arm_group_label>Sorafenib (Nexavar, BAY43-9006) &amp; Levothyroxine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects between the ages of 18 (inclusive) and 45 years (inclusive) at
             the first screening visit.

          -  Body mass index (BMI) between 18.5 (inclusive) to 30.0 kg / m² (inclusive) with body
             weight ≥ 65kg.

          -  Normal thyroid function indicated by thyroid examination to include total and free T3
             (Triiodothyronine) , T4 (total and free Thyroxine, levothyroxine), TSH (Thyroid
             stimulating hormone), anti-TSH-receptor (anti-TSHR) antibody, anti-thyroperoxidase
             (anti-TPO) antibody, anti-thyroglobulin antibody (anti-ATA) as well as thyroid
             ultrasound.

        Exclusion Criteria:

          -  History of clinically significant metabolic, renal, hepatic, or central nervous system
             disorder such as seizure, psychosis and sleep disorders.

          -  History of cardiovascular diseases including arrhythmia, hypertension, ischemia, etc.

          -  Known or suspected cardiovascular disease including potential risk of atrioventricular
             (AV) block, arrhythmia, etc. with or without a formal cardiologist consultation.

          -  Subjects who had received iodine containing contrast medium within 2 months before
             first study drug administration.

          -  Use of systemic or topical medicines or substances which might affect the study
             drug(s) must be avoided
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>January 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2015</study_first_posted>
  <last_update_submitted>October 9, 2015</last_update_submitted>
  <last_update_submitted_qc>October 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sorafenib, levothyroxine, drug interaction, pharmacokinetics, healthy volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

